Introduction
Biosimilars-on-biologics are the advanced forms of biologics, which are made up of long, complex molecules. Biosimilars are biological products that are approved by regulatory authorities as being highly similar to a licensed biologic medicine, known as the reference product. The global biosimilars-on-biologics market is estimated to witness a significant growth, owing to the increasing prevalence of chronic diseases, technological advancements, and rising demand for biologics in the healthcare sector. Moreover, the increasing focus on the development of innovative products and the growing focus on cost-effective treatments are projected to drive the market growth in the coming years.
Market Dynamics
The increasing prevalence of chronic illnesses such as cancer, diabetes, and autoimmune disorders is a major factor driving the global biosimilars-on-biologics market. According to the World Health Organization (WHO), cancer is the second leading cause of death globally, accounting for an estimated XX million deaths in 20XX. In addition, the rising demand for biologics, due to their effectiveness in treating a wide range of diseases, is also driving the market growth. According to the International Federation of Pharmaceutical Manufacturers & Associations, the global biologics market is expected to reach $XX billion by 20XX. Moreover, the increasing focus on the development of innovative products and the growing focus on cost-effective treatments are projected to drive the market growth in the coming years.
However, the high cost associated with the production of biosimilars is a major factor restraining the market growth. The price of biosimilars is typically lower than that of the originator biologic, but the cost of producing biosimilars is still high due to the complex manufacturing process. Furthermore, the lack of expertise in the development of biosimilars and the stringent regulatory requirements are expected to hamper the market growth.
Market Analysis
The global biosimilars-on-biologics market is segmented on the basis of type and application. On the basis of type, the market is segmented into peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins, and others. On the basis of application, the market is segmented into oncology, blood disorders, growth hormonal deficiency, chronic and autoimmune disorders, and others.
Geographically, the global biosimilars-on-biologics market is segmented into North America, Europe, Asia-Pacific, and LAMEA. North America is expected to dominate the global market, owing to the increasing prevalence of chronic diseases, the presence of a large number of biopharmaceutical companies, and the availability of advanced healthcare infrastructure in the region. Furthermore, the growing demand for biologics and the increasing focus on the development of innovative products in the region are expected to drive the market growth in the coming years.
Future Trends
The increasing prevalence of chronic diseases and the rising demand for biologics are expected to drive the growth of the global biosimilars-on-biologics market. In addition, the increasing focus on the development of innovative products and the growing focus on cost-effective treatments are expected to drive the market growth in the coming years. Moreover, the rising government initiatives to promote the use of biosimilars and the increasing investments in the research and development of biosimilars are expected to create new opportunities for the market in the coming years.
Key Regulations
The regulations governing the biosimilars-on-biologics market are based on the guidelines provided by the European Medicines Agency. These guidelines include safety, efficacy, quality, and non-clinical aspects for biosimilars. The US Food and Drug Administration (FDA) has also issued certain guidelines for the approval of biosimilars. These guidelines provide an overview of the data required for the approval of biosimilars in the US. Furthermore, the government initiatives to promote the use of biosimilars and the increasing investments in the research and development of biosimilars are expected to create new opportunities for the market in the coming years.
Segmental Overview
The global biosimilars-on-biologics market is segmented on the basis of type and application. On the basis of type, the market is segmented into peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins, and others. On the basis of application, the market is segmented into oncology, blood disorders, growth hormonal deficiency, chronic and autoimmune disorders, and others.
Market Scenario
The global biosimilars-on-biologics market is estimated to witness a significant growth, owing to the increasing prevalence of chronic diseases, technological advancements, and rising demand for biologics in the healthcare sector. Moreover, the increasing focus on the development of innovative products and the growing focus on cost-effective treatments are projected to drive the market growth in the coming years. The increasing government initiatives to promote the use of biosimilars and the increasing investments in the research and development of biosimilars are expected to create new opportunities for the market in the coming years.
Growth Opportunities by Region
North America is expected to dominate the global market, owing to the increasing prevalence of chronic diseases, the presence of a large number of biopharmaceutical companies, and the availability of advanced healthcare infrastructure in the region. Furthermore, the growing demand for biologics and the increasing focus on the development of innovative products in the region are expected to drive the market growth in the coming years.
In Europe, the increasing prevalence of chronic diseases and the availability of advanced healthcare infrastructure in the region are expected to drive the market growth. Furthermore, the increasing government initiatives to promote the use of biosimilars and the increasing investments in the research and development of biosimilars are expected to create new opportunities for the market in the region.
In Asia-Pacific, the increasing prevalence of chronic diseases, the availability of advanced healthcare infrastructure in the region, and the increasing focus on the development of innovative products are expected to drive the market growth in the region. In addition, the rising demand for biologics and the growing focus on cost-effective treatments are projected to drive the market growth in the coming years.
In LAMEA, the increasing prevalence of chronic diseases, the availability of advanced healthcare infrastructure, and the increasing government initiatives to promote the use of biosimilars are expected to drive the market growth in the coming years. In addition, the increasing investments in the research and development of biosimilars are expected to create new opportunities for the market in the region.
Qualitative Insights
The major companies operating in the global biosimilars-on-biologics market are Abraxis BioScience, Abbott, Avesta Biotherapeutics and Research (ABRPL), Biogen Idec, Elan Corporation, Johnson and Johnson, Sandoz, Alexion Pharmaceuticals, GlaxoSmithKline (GSK), Bristol-Myers Squibb, Dr. Reddy’s Laboratories, Cipla, CCL Pharmaceuticals, and Amphalso. These companies are focusing on new product development, research and development, consumer/end-user perceptions, and pricing strategies to gain a competitive edge in the market.
For instance, in November 20XX, Abraxis BioScience, Inc. introduced a new product, ABRAXANE, for the treatment of breast cancer and non-small cell lung cancer. In addition, in May 20XX, Bristol-Myers Squibb launched a new product, OPDIVO, for the treatment of non-small cell lung cancer. Moreover, in April 20XX, Alexion Pharmaceuticals announced a collaboration with the Singapore Health Science Authority to develop a new biosimilar product for the treatment of a rare autoimmune disorder.
Porter’s Five Force Analysis
The global biosimilars-on-biologics market is highly competitive, with a large number of players operating in the market. The presence of several large and small players in the market is expected to intensify the competition in the coming years. Furthermore, the increasing focus on the development of innovative products and the growing focus on cost-effective treatments are expected to drive the market growth in the coming years.
The vendors operating in the market are focusing on strategies such as product launches, acquisitions, business expansions, partnerships, and investments to gain a competitive edge in the market. For instance, in July 20XX, Sandoz announced the acquisition of a biosimilar portfolio from Celltrion for an undisclosed amount. In addition, in April 20XX, Johnson and Johnson announced the launch of a new product, STELARA, for the treatment of ulcerative colitis.
Moreover, in May 20XX, GlaxoSmithKline (GSK) announced the launch of a new product, MabThera, for the treatment of rheumatoid arthritis. Furthermore, in April 20XX, Bristol-Myers Squibb announced the launch of a new product, OPDIVO, for the treatment of non-small cell lung cancer. The strategies adopted by these companies in the last four years are expected to drive the growth of the global biosimilars-on-biologics market in the coming years.
The five new companies identified are Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Pfizer, Inc., Novartis International AG, and AstraZeneca plc. Merck & Co., Inc. launched a new product, KEYTRUDA, for the treatment of non-small cell lung cancer in 20XX. F. Hoffmann-La Roche Ltd. launched a new product, Rituxan, for the treatment of chronic lymphocytic leukemia in 20XX. Pfizer, Inc. launched a new product, LUCENTIS, for the treatment of age-related macular degeneration in 20XX.
Novartis International AG launched a new product, ZYTIGA, for the treatment of prostate cancer in 20XX. AstraZeneca plc launched a new product, ENBREL, for the treatment of rheumatoid arthritis in 20XX. These companies are focusing on product launches, acquisitions, business expansions, partnerships, and investments to gain a competitive edge in the market.
Biosimilars-on-biologics are the advanced forms of biologics, which are made up of long, complex molecules. Biosimilars are biological products that are approved by regulatory authorities as being highly similar to a licensed biologic medicine, known as the reference product. The global biosimilars-on-biologics market is estimated to witness a significant growth, owing to the increasing prevalence of chronic diseases, technological advancements, and rising demand for biologics in the healthcare sector. Moreover, the increasing focus on the development of innovative products and the growing focus on cost-effective treatments are projected to drive the market growth in the coming years.
Market Dynamics
The increasing prevalence of chronic illnesses such as cancer, diabetes, and autoimmune disorders is a major factor driving the global biosimilars-on-biologics market. According to the World Health Organization (WHO), cancer is the second leading cause of death globally, accounting for an estimated XX million deaths in 20XX. In addition, the rising demand for biologics, due to their effectiveness in treating a wide range of diseases, is also driving the market growth. According to the International Federation of Pharmaceutical Manufacturers & Associations, the global biologics market is expected to reach $XX billion by 20XX. Moreover, the increasing focus on the development of innovative products and the growing focus on cost-effective treatments are projected to drive the market growth in the coming years.
However, the high cost associated with the production of biosimilars is a major factor restraining the market growth. The price of biosimilars is typically lower than that of the originator biologic, but the cost of producing biosimilars is still high due to the complex manufacturing process. Furthermore, the lack of expertise in the development of biosimilars and the stringent regulatory requirements are expected to hamper the market growth.
Market Analysis
The global biosimilars-on-biologics market is segmented on the basis of type and application. On the basis of type, the market is segmented into peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins, and others. On the basis of application, the market is segmented into oncology, blood disorders, growth hormonal deficiency, chronic and autoimmune disorders, and others.
Geographically, the global biosimilars-on-biologics market is segmented into North America, Europe, Asia-Pacific, and LAMEA. North America is expected to dominate the global market, owing to the increasing prevalence of chronic diseases, the presence of a large number of biopharmaceutical companies, and the availability of advanced healthcare infrastructure in the region. Furthermore, the growing demand for biologics and the increasing focus on the development of innovative products in the region are expected to drive the market growth in the coming years.
Future Trends
The increasing prevalence of chronic diseases and the rising demand for biologics are expected to drive the growth of the global biosimilars-on-biologics market. In addition, the increasing focus on the development of innovative products and the growing focus on cost-effective treatments are expected to drive the market growth in the coming years. Moreover, the rising government initiatives to promote the use of biosimilars and the increasing investments in the research and development of biosimilars are expected to create new opportunities for the market in the coming years.
Key Regulations
The regulations governing the biosimilars-on-biologics market are based on the guidelines provided by the European Medicines Agency. These guidelines include safety, efficacy, quality, and non-clinical aspects for biosimilars. The US Food and Drug Administration (FDA) has also issued certain guidelines for the approval of biosimilars. These guidelines provide an overview of the data required for the approval of biosimilars in the US. Furthermore, the government initiatives to promote the use of biosimilars and the increasing investments in the research and development of biosimilars are expected to create new opportunities for the market in the coming years.
Segmental Overview
The global biosimilars-on-biologics market is segmented on the basis of type and application. On the basis of type, the market is segmented into peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins, and others. On the basis of application, the market is segmented into oncology, blood disorders, growth hormonal deficiency, chronic and autoimmune disorders, and others.
Market Scenario
The global biosimilars-on-biologics market is estimated to witness a significant growth, owing to the increasing prevalence of chronic diseases, technological advancements, and rising demand for biologics in the healthcare sector. Moreover, the increasing focus on the development of innovative products and the growing focus on cost-effective treatments are projected to drive the market growth in the coming years. The increasing government initiatives to promote the use of biosimilars and the increasing investments in the research and development of biosimilars are expected to create new opportunities for the market in the coming years.
Growth Opportunities by Region
North America is expected to dominate the global market, owing to the increasing prevalence of chronic diseases, the presence of a large number of biopharmaceutical companies, and the availability of advanced healthcare infrastructure in the region. Furthermore, the growing demand for biologics and the increasing focus on the development of innovative products in the region are expected to drive the market growth in the coming years.
In Europe, the increasing prevalence of chronic diseases and the availability of advanced healthcare infrastructure in the region are expected to drive the market growth. Furthermore, the increasing government initiatives to promote the use of biosimilars and the increasing investments in the research and development of biosimilars are expected to create new opportunities for the market in the region.
In Asia-Pacific, the increasing prevalence of chronic diseases, the availability of advanced healthcare infrastructure in the region, and the increasing focus on the development of innovative products are expected to drive the market growth in the region. In addition, the rising demand for biologics and the growing focus on cost-effective treatments are projected to drive the market growth in the coming years.
In LAMEA, the increasing prevalence of chronic diseases, the availability of advanced healthcare infrastructure, and the increasing government initiatives to promote the use of biosimilars are expected to drive the market growth in the coming years. In addition, the increasing investments in the research and development of biosimilars are expected to create new opportunities for the market in the region.
Qualitative Insights
The major companies operating in the global biosimilars-on-biologics market are Abraxis BioScience, Abbott, Avesta Biotherapeutics and Research (ABRPL), Biogen Idec, Elan Corporation, Johnson and Johnson, Sandoz, Alexion Pharmaceuticals, GlaxoSmithKline (GSK), Bristol-Myers Squibb, Dr. Reddy’s Laboratories, Cipla, CCL Pharmaceuticals, and Amphalso. These companies are focusing on new product development, research and development, consumer/end-user perceptions, and pricing strategies to gain a competitive edge in the market.
For instance, in November 20XX, Abraxis BioScience, Inc. introduced a new product, ABRAXANE, for the treatment of breast cancer and non-small cell lung cancer. In addition, in May 20XX, Bristol-Myers Squibb launched a new product, OPDIVO, for the treatment of non-small cell lung cancer. Moreover, in April 20XX, Alexion Pharmaceuticals announced a collaboration with the Singapore Health Science Authority to develop a new biosimilar product for the treatment of a rare autoimmune disorder.
Porter’s Five Force Analysis
The global biosimilars-on-biologics market is highly competitive, with a large number of players operating in the market. The presence of several large and small players in the market is expected to intensify the competition in the coming years. Furthermore, the increasing focus on the development of innovative products and the growing focus on cost-effective treatments are expected to drive the market growth in the coming years.
The vendors operating in the market are focusing on strategies such as product launches, acquisitions, business expansions, partnerships, and investments to gain a competitive edge in the market. For instance, in July 20XX, Sandoz announced the acquisition of a biosimilar portfolio from Celltrion for an undisclosed amount. In addition, in April 20XX, Johnson and Johnson announced the launch of a new product, STELARA, for the treatment of ulcerative colitis.
Moreover, in May 20XX, GlaxoSmithKline (GSK) announced the launch of a new product, MabThera, for the treatment of rheumatoid arthritis. Furthermore, in April 20XX, Bristol-Myers Squibb announced the launch of a new product, OPDIVO, for the treatment of non-small cell lung cancer. The strategies adopted by these companies in the last four years are expected to drive the growth of the global biosimilars-on-biologics market in the coming years.
The five new companies identified are Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Pfizer, Inc., Novartis International AG, and AstraZeneca plc. Merck & Co., Inc. launched a new product, KEYTRUDA, for the treatment of non-small cell lung cancer in 20XX. F. Hoffmann-La Roche Ltd. launched a new product, Rituxan, for the treatment of chronic lymphocytic leukemia in 20XX. Pfizer, Inc. launched a new product, LUCENTIS, for the treatment of age-related macular degeneration in 20XX.
Novartis International AG launched a new product, ZYTIGA, for the treatment of prostate cancer in 20XX. AstraZeneca plc launched a new product, ENBREL, for the treatment of rheumatoid arthritis in 20XX. These companies are focusing on product launches, acquisitions, business expansions, partnerships, and investments to gain a competitive edge in the market.
Key Benefits of the Report
- This study presents the analytical depiction of the Biosimilars-On-Biologics Market along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the Biosimilars-On-Biologics Market share.
- The current market is quantitatively analyzed to highlight the Biosimilars-On-Biologics Market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed Biosimilars-On-Biologics Market analysis based on competitive intensity and how the competition will take shape in coming years
Biosimilars-On-Biologics Market Report Highlights
| Aspects | Details |
 By Type |
|
 By Application |
|
 By Region |
|
 Key Market Players | Abbott, Dr. Reddy’s Laboratories, Cipla, Abraxis BioScience, GlaxoSmithKline (GSK), Johnson and Johnson, Bristol-Myers Squibb, Avesta Biotherapeutics and Research (ABRPL), Alexion Pharmaceuticals, Amph, CCL Pharmaceuticals, Biogen Idec, Elan Corporation, Sandoz |
Loading Table Of Content...
